What is PathOtrak?
PathOtrak is a specialized biotechnology firm focused on the rapid detection of foodborne pathogens. The company has developed a proprietary Next Generation Extraction (NGE) System that drastically reduces incubation times, delivering actionable results in as little as two hours. This innovation is both USDA and FDA compliant, providing a robust solution for the fresh produce, poultry, and beef industries. By optimizing laboratory workflows and reducing the consumption of expensive reagents by up to 50%, PathOtrak addresses a critical pain point in industrial food safety. The company's technology is not merely a diagnostic tool but a comprehensive efficiency platform that enables food processors to maintain high safety standards while simultaneously reducing operational overhead and supply chain bottlenecks.
How much funding has PathOtrak raised?
PathOtrak has raised a total of $2.8M across 3 funding rounds:
Other Financing Round
$300K
Other Financing Round
$300K
Debt
$2.2M
Other Financing Round (2023): $300K with participation from Tedco
Other Financing Round (2024): $300K led by Tedco
Debt (2025): $2.2M, investors not publicly disclosed
Key Investors in PathOtrak
Tedco
TEDCO, the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for PathOtrak?
With this recent capital infusion, PathOtrak is expected to scale its manufacturing capabilities and expand its commercial footprint across the North American food processing market. The strategic focus will likely shift toward deepening its integration within large-scale industrial supply chains, where rapid pathogen detection is essential for regulatory compliance and brand protection. Furthermore, the company is well-positioned to explore additional applications for its NGE technology, potentially diversifying into broader environmental sampling and clinical diagnostics. As PathOtrak matures, the emphasis will remain on maintaining its competitive advantage through technological superiority and cost-efficiency, ensuring that it remains a preferred partner for enterprises seeking to mitigate biological risks in food production.
See full PathOtrak company page
